BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022)
BioXcel Therapeutics (BTAI) posted quarterly Long-Term Debt Issuances of $30.0 million for Q3 2022, up 8186.25% quarter-over-quarter from -$371000.0 in Q1 2018.
BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022) Analysis & Trends
BioXcel Therapeutics' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $30.0 million for Q3 2022.
- In Q3 2022, Long-Term Debt Issuances changed N/A year-over-year to $30.0 million; the TTM figure through Dec 2022 stood at $30.0 million (changed N/A YoY), while the FY2022 annual figure was $98.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q3 2022 stood at $30.0 million, up from -$371000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $30.0 million in Q3 2022, with the low at -$371000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.46 Mn | 24.46 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 30.00 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Mar 31, 2018 | -371,000.00 |
| Mar 31, 2018 | -371,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Sep 30, 2017 | 84,000.00 |
| Sep 30, 2017 | 84,000.00 |